<qa>  What is the total duration of the trial planned to be?The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension week 104 followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks 5 years. 